Cayston (Aztreonam Lysine) Patent Expiration, LOE Window & CMS Spending

Cayston (Aztreonam Lysine) by Gilead Sciences: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $69.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN050814 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$69.1M
2024 Medicare Part D Spend$34.4M
2024 Medicaid Spend$34.7M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 22.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.